Abstract
Although remarkable therapeutic advances in the treatment of cardiometabolic disorders have been made with current therapeutic options, cardiovascular disease (CVD) is still a leading cause of mortality and morbidity in the Western world. Therefore, to develop a novel therapeutic strategy is needed for the prevention of cardiovascular disease (CVD) in high-risk patients for atherosclerosis. Recently, we, along with others, have shown that pigment epithelium-derived factor (PEDF), a glycoprotein with potent neuronal differentiating activity, exerts anti-oxidative and anti-inflammatory properties in vascular wall cells, leukocytes and platelets. In addition, PEDF not only suppresses neointimal hyperplasia after balloon angioplasty, but also blocks occlusive thrombus formation in a rat arterial thrombosis model. These observations suggest that substitution of PEDF may be a novel therapeutic strategy for atherosclerosis. This article summarizes the pathophysiological role of PEDF in atherosclerosis and its potential therapeutic implication in this devastating disorder. We also discuss here the kinetics and regulation of PEDF in cardiometabolic disorders in humans.
Keywords: Atherosclerosis, cardiometabolic disease, oxidative stress, PEDF
Current Pharmaceutical Design
Title: Atheroprotective Properties of Pigment Epithelium-Derived Factor (PEDF) in Cardiometabolic Disorders
Volume: 15 Issue: 9
Author(s): Sho-ichi Yamagishi, Takanori Matsui and Kazuo Nakamura
Affiliation:
Keywords: Atherosclerosis, cardiometabolic disease, oxidative stress, PEDF
Abstract: Although remarkable therapeutic advances in the treatment of cardiometabolic disorders have been made with current therapeutic options, cardiovascular disease (CVD) is still a leading cause of mortality and morbidity in the Western world. Therefore, to develop a novel therapeutic strategy is needed for the prevention of cardiovascular disease (CVD) in high-risk patients for atherosclerosis. Recently, we, along with others, have shown that pigment epithelium-derived factor (PEDF), a glycoprotein with potent neuronal differentiating activity, exerts anti-oxidative and anti-inflammatory properties in vascular wall cells, leukocytes and platelets. In addition, PEDF not only suppresses neointimal hyperplasia after balloon angioplasty, but also blocks occlusive thrombus formation in a rat arterial thrombosis model. These observations suggest that substitution of PEDF may be a novel therapeutic strategy for atherosclerosis. This article summarizes the pathophysiological role of PEDF in atherosclerosis and its potential therapeutic implication in this devastating disorder. We also discuss here the kinetics and regulation of PEDF in cardiometabolic disorders in humans.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi, Matsui Takanori and Nakamura Kazuo, Atheroprotective Properties of Pigment Epithelium-Derived Factor (PEDF) in Cardiometabolic Disorders, Current Pharmaceutical Design 2009; 15 (9) . https://dx.doi.org/10.2174/138161209787581940
DOI https://dx.doi.org/10.2174/138161209787581940 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of BNP and CRP as Biomarkers in Assessing Cardiovascular Disease:Diagnosis Versus Risk
Current Vascular Pharmacology Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews Perfusion MRI of Brain Neoplams
Current Medical Imaging The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer
Current Cancer Drug Targets Glioma Dynamics and Computational Models: A Review of Segmentation, Registration, and In Silico Growth Algorithms and their Clinical Applications
Current Medical Imaging Current Paradigms in COVID-19 Research: Proposed Treatment Strategies, Recent Trends and Future Directions
Current Medicinal Chemistry Beta-blockers in Intensive Care Medicine: Potential Benefit in Acute Brain Injury and Acute Respiratory Distress Syndrome
Recent Patents on Cardiovascular Drug Discovery Management of the Low Cardiac Output Syndrome Following Surgery for Congenital Heart Disease
Current Cardiology Reviews Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel Strategies for the Detection of Systolic and Diastolic Heart Failure
Current Cardiology Reviews Promising Anti-stroke Signature of Voglibose: Investigation through In- Silico Molecular Docking and Virtual Screening in In-Vivo Animal Studies
Current Gene Therapy Recent Updates on Biological Activities of Oxadiazoles
Mini-Reviews in Medicinal Chemistry Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry